Bandhan Mutual Fund buys EPL Limited

Bandhan Mutual Fund made a ~₹50 crore bulk buy in EPL Limited earlier this month — 20,82,465 shares at ₹240.0, dated September 1, 2026, and confirmed in exchange bulk-deal data.

CMP ₹239 (as of Sept 21, 2026) · Market cap ~₹7,659 crore · P/E ~19-27x (vs. Huhtamaki India's ~13.4x, a smaller listed flexible-packaging peer)

What EPL Limited actually does

EPL makes the flexible squeeze tubes you see on toothpaste, face wash, and cosmetic cream products — the soft, squeezable packaging, not rigid bottles or cans. It's one of the largest makers of these tubes globally, with factories across India, Poland, Germany, Thailand, and other countries, selling almost entirely to large multinational consumer-goods companies rather than directly to shoppers.

Its supply contracts are structured on a "blended cost basis," meaning raw material, freight, and currency cost changes are contractually passed through to customers via pricing — a real structural protection for margins, in contrast to EPL's own post-COVID experience when cost recovery failed. Historically Oral Care (toothpaste tubes) was its biggest business; the company is now deliberately growing its Beauty & Cosmetics tube business, which carries structurally higher margins. It's also in the process of merging with a larger packaging company, Indovida, which would nearly double its scale and add rigid-plastic formats and new geographies.

Q1 FY27: a genuine record quarter, with one real wrinkle

Revenue grew 25.3% YoY — management called this the fastest top-line growth in the company's history, and the fifth straight quarter of double-digit revenue growth. Underlying EBITDA margin reached 19.6%, close to the 20% target.

Metric Q1 FY27 Note --------- Revenue growth (YoY) +25.3% Fastest in company history; ~20% excluding one-off pass-through pricing effect EBITDA growth (YoY) +15.2% Reported margin 18.8%; underlying 19.6% PAT -1.4% YoY Despite revenue/EBITDA growth — see below PBT growth (YoY) +10% The cleaner read on operating performance this quarter ROCE 18.5% —

The one wrinkle: PAT actually fell 1.4% even as revenue and EBITDA grew strongly. The reason is a higher effective tax rate this quarter (~22%, up from ~18% a year earlier) as the company laps an unusually low tax base from last year — not a sign of weakening operations. PBT (profit before this tax effect) grew a healthy 10%.

Why revenue growth alone doesn't tell the full story here A company can show flat or falling profit for reasons that have nothing to do with the business itself — in this case, a tax-rate comparison quirk, not weaker sales or margins. Management says double-digit PAT growth remains on track for the full year once this base effect washes out.

The Beauty & Cosmetics opportunity — and why it's a multi-year story

EPL currently holds just 8% global market share in Beauty & Cosmetics tubes and is targeting a doubling to 16% "in the next few years." This category now makes up 54% of the company's overall portfolio (branded "Personal Care & Beyond"), up from a historical base dominated by lower-margin Oral Care. Management has built dedicated sales teams and a "Centre of Excellence" in India specifically for this category — a real, structural investment, not just a stated ambition.

The Indovida merger

The Competition Commission of India has approved EPL's proposed merger with Indovida, though final regulatory approval is still pending. Indovida itself posted a Q1 EBITDA of ₹383 crore at a 27% margin (up 614 basis points) — the CFO called it a "very, very EPS-accretive merger," with Indovida's own PAT comparable in size to EPL's. If it completes, this would meaningfully change EPL's scale and geographic footprint, adding rigid-plastic packaging formats it doesn't currently make.

Management's guidance

Per the Q1 FY27 concall:

- Revenue growth: raised from "early/low double digits" to "high teens" for the next few quarters - EBITDA margin: 20% underlying target maintained - PAT: double-digit growth still expected for the full year, despite Q1's tax-driven dip - Effective tax rate: guided at 20-22% for full-year FY27 (vs. 18% in FY26) - Beauty & Cosmetics market share: targeting a doubling from 8% to 16% "in the next few years"

These are management's own forward-looking statements, not guaranteed outcomes.

The part of the call that got a vague answer

An analyst pressed management on whether Europe's margin problems (currently below the mid-teens target, due to manufacturing-consolidation costs in Poland) were a one-time transition cost or an ongoing drag. Management confirmed the challenges are ongoing, not one-time — but declined to quantify the actual transitional cost amount, and gave only a vague "coming quarters" timeline for recovery. That's a real, disclosed gap in visibility, not a resolved issue.

Risks worth flagging

- Europe's margin drag — ongoing, unquantified, with no firm recovery date - Working capital jump — net working capital rose ~₹180 crore in this single quarter alone, versus ₹170 crore for all of FY26, driven by inventory cost inflation and safety-stock buildup - Indovida merger — CCI-approved but final regulatory approval still pending; the broader strategic pivot depends on this completing - Persistent input-cost inflation — management expects "a high inflationary environment for some time," even with pass-through contracts in place - Americas margin pressure — sequential EBITDA declined there due to ahead-of-curve investment spending, not weaker demand

Note: I am not a SEBI-registered investment advisor. This article is for educational purposes only and is not investment advice. Please consult a registered financial advisor before making investment decisions.

Sources

- https://www.tickertape.in/stocks/epl-ESSL - https://www.screener.in/company/HUHTAMAKI/